RecruitingEarly Phase 1NCT06428708

[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma

Comparison of [18F] PSMA-1007 PET/CT and Conventional Imaging in the Detection of Metastatic Clear Cell Renal Cell Carcinoma


Sponsor

Western University

Enrollment

30 participants

Start Date

Jan 24, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special type of imaging scan called PSMA PET/CT — a highly sensitive nuclear medicine scan — to look for cancer spread in people with advanced kidney cancer (renal cell carcinoma). The study aims to see if this scan can detect cancer that conventional CT or MRI scans might miss. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with metastatic renal cell carcinoma (kidney cancer that has spread) - Your cancer has a clear cell component (the most common type) - You have had a recent contrast-enhanced CT or MRI scan of your chest, abdomen, and pelvis within the past 5 weeks **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your kidney cancer does not have any clear cell components - You cannot lie flat for 30 minutes for the scan - You have had another type of cancer in the past (except non-melanoma skin cancer) - You cannot provide informed consent - Your liver function is inadequate - Your cancer requires urgent treatment that would begin before the scan can happen - You have already received systemic or radiation treatment for cancer (other than skin cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST[18F] PSMA-1007 PET/CT

\[18F\] PSMA-1007 PET/CT scan


Locations(1)

London Health Sciences Centre - Victoria Hospital

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06428708


Related Trials